8-Methyl-3-piperidin-1-yl-8-azabicyclo[3.2.1]octane | 125541-18-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: 8-Methyl-3-piperidin-1-yl-8-azabicyclo[3.2.1]octane
• CAS: 125541-18-6
• 化学式: C₁₃H₂₄N₂
• 分子量: 208.347
• InChiKey: MVSSXDKAQLWYQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  哌啶 、 托品酮 在 titanium(IV) isopropylate 、 sodium tetrahydroborate 作用下， 以58%的产率得到8-Methyl-3-piperidin-1-yl-8-azabicyclo[3.2.1]octane
  参考文献：
  名称：

  An improved method for reductive alkylation of amines using titanium(IV) isopropoxide and sodium cyanoborohydride

  摘要：

  DOI：

  10.1021/jo00295a060

文献信息

• MATTSON, RONALD J.;PHAM, KAHNIE M.;LEUCK, DAVID J.;COWEN, KENNETH A., J. ORG. CHEM., 55,(1990) N, C. 2552-2554
  作者：MATTSON, RONALD J.、PHAM, KAHNIE M.、LEUCK, DAVID J.、COWEN, KENNETH A.

  DOI：——

  日期：——
• Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors
  申请人：Josien Hubert B.

  公开号：US20100087425A1

  公开（公告）日：2010-04-08

  This invention discloses novel gamma secretase inhibitors of the formula: wherein: L is —O—, —N(R 6 )—, —S—, —S(O)—, or —S(O 2 )—; R 1 is selected from the group consisting of aryl and heteroaryl; R 2 is selected from the group consisting of alkyl, —C(O)—Y, —X—C(O)—Y, -alkylene-X—C(O)—Y, -alkylene-C(O)—Y, -alkylene-cycloalkylene-X—C(O)—Y, -alkylene-cycloalkylene-C(O)—Y, -cycloalkylene-alkylene-X—C(O)—Y, -cycloalkylene-alkylene-C(O)—Y, -cycloalkylene-X—C(O)—Y, -cycloalkylene-C(O)—Y, -alkylene-cycloalkylene-alkylene-X—C(O)—Y, -alkylene-cycloalkylene-alkylene-C(O)—Y, aryl, and heteroaryl; R 3 is selected from the group consisting of aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, arylheterocycloalkyl, and alkoxyalkyl; each R 4 and R 5 is independently selected from the group consisting of H and alkyl; and Y is selected from the group consisting of —NR 8 R 9 , —N(R 6 )—(CH 2 ) b —NR 8 R 9 , aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, and aryl heterocycloalkyl; or Y is selected from the group consisting of: One or more compounds of formula I, or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.
• US7763613B2
  申请人：——

  公开号：US7763613B2

  公开（公告）日：2010-07-27
• US7998958B2
  申请人：——

  公开号：US7998958B2

  公开（公告）日：2011-08-16
• [EN] nSMASE2 INHIBITOR PRODRUGS WITH ENHANCED ORAL AND BRAIN EXPOSURES<br/>[FR] PROMÉDICAMENTS D'INHIBITEURS DE NSMASE2 À EXPOSITIONS BUCCALES ET CÉRÉBRALES AMÉLIORÉES
  申请人：[en]THE JOHNS HOPKINS UNIVERSITY

  公开号：WO2022261120A1

  公开（公告）日：2022-12-15

  Prodrugs of small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) and their use for treating neurodegenerative diseases, such as, neurodegenerative diseases associated with high levels of ceramide, including, but not limited to Alzheimer's disease (AD), HIV-associated neurocognitive disorder (HAND), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and, in other aspects, for treating cancer, are provided.